NCT05577728View on ClinicalTrials.gov

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

2,316

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

New use of semaglutide injection

New use of semaglutide injection dispensing claim is used as the exposure.

DRUG

"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"

"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER